This case adds to the limited body of evidence and underscores the importance of recognizing neuroendocrine differentiation in ALK-positive lung cancer cases which show clinical progression. Further studies are needed to elucidate the molecular drivers of this transformation and to optimize treatment strategies for affected patients.

5 days ago

Journal

ALK (Anaplastic lymphoma kinase)

ALK positive • ALK translocation

Alecensa (alectinib)

CircRNAs derived from the tyrosine phosphatase PTPN22 impact chemosensitivity in ALK-positive T-cell lymphomas. (PubMed, Sci Rep)

Loss of CARM1 expression promoted drug tolerance in chemosensitive ALK(+) lymphoma cells. These findings identify the circPTPN22/CARM1 axis as a regulator of chemosensitivity and propose CARM1 inhibition as a potential strategy to overcome chemoresistance in patients with ALK(+) ALCL.

7 days ago

Journal

ALK (Anaplastic lymphoma kinase) • PTPN22 (Protein Tyrosine Phosphatase Non-Receptor Type 22)

ALK positive • ALK translocation

CR-001-101: A Phase 1/2, Multicenter, Open-label, Dose Escalation and Dose Expansion Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of CR-001 in Adult Participants with Locally Advanced or Metastatic Solid Tumors (2025-523590-42-00)

P1/2, N=44, Not yet recruiting, Crescent Biopharma Inc.

8 days ago

New P1/2 trial

PD-L1 (Programmed death ligand 1) • ALK (Anaplastic lymphoma kinase)

PD-L1 expression • EGFR mutation • ALK translocation

14d

KN046-209: Study of KN046 in Subjects With Advanced Non-Small Cell Lung Cancer (clinicaltrials.gov)

P2, N=95, Completed, Jiangsu Alphamab Biopharmaceuticals Co., Ltd | Recruiting --> Completed | N=54 --> 95 | Trial completion date: Dec 2027 --> Dec 2025

14 days ago

Trial completion • Enrollment change • Trial completion date

EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1) • ALK (Anaplastic lymphoma kinase)

ALK translocation • EGFR negative

axitinib • erfonrilimab (KN046)

28d

ACHIEVE Study: Chemotherapy Combined With Immunotherapy Versus Immunotherapy Alone for Older Adults With Stage IIIB-IV Lung Cancer, The ACHIEVE Trial (clinicaltrials.gov)

P3, N=304, Recruiting, National Cancer Institute (NCI) | Trial completion date: Jun 2026 --> Jan 2035 | Trial primary completion date: Jun 2026 --> Jan 2035

28 days ago

Trial completion date • Trial primary completion date

EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1) • ALK (Anaplastic lymphoma kinase)

ALK translocation • EGFR negative

Keytruda (pembrolizumab) • carboplatin • albumin-bound paclitaxel • pemetrexed

ATATcH Alternating Treatment Plans for Advanced Cancer (clinicaltrials.gov)

P2, N=150, Recruiting, Rutgers, The State University of New Jersey | Trial completion date: Dec 2025 --> May 2028 | Trial primary completion date: May 2025 --> May 2027

1 month ago

Trial completion date • Trial primary completion date

EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1) • BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • MET (MET proto-oncogene, receptor tyrosine kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)

PD-L1 expression • EGFR mutation • BRAF mutation • BRAF V600 • MET exon 14 mutation • MET mutation • ALK translocation

Keytruda (pembrolizumab) • carboplatin • 5-fluorouracil • albumin-bound paclitaxel • pemetrexed

Phase I/II Study of the Anti-Programmed Death Ligand-1 Durvalumab Antibody (MEDI4736) in Combination With Olaparib and/or Cediranib for Advanced Solid Tumors and Advanced or Recurrent Ovarian, Triple Negative Breast, Lung, Prostate and Colorectal Can... (clinicaltrials.gov)

P1/2, N=268, Active, not recruiting, National Cancer Institute (NCI) | Trial primary completion date: Apr 2026 --> Oct 2027 | Trial completion date: Jul 2026 --> Oct 2027

1 month ago

Trial completion date • Trial primary completion date • IO biomarker

EGFR (Epidermal growth factor receptor) • HER-2 (Human epidermal growth factor receptor 2) • BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • PGR (Progesterone receptor) • BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset)

BRAF V600E • BRCA2 mutation • BRCA1 mutation • EGFR mutation • BRAF V600 • ALK translocation

Lynparza (olaparib) • Imfinzi (durvalumab) • Recentin (cediranib)

2ms

QUILT2023: Nogapendekin Alfa Inbakicept for Advanced Non-Small Cell Lung Cancer (clinicaltrials.gov)

P3, N=102, Terminated, ImmunityBio, Inc. | N=1538 --> 102 | Trial completion date: Dec 2026 --> Oct 2025 | Active, not recruiting --> Terminated | Trial primary completion date: Oct 2026 --> Oct 2025; There are no longer active subjects on QUILT-2.023. Data will be entered into clinicaltrials.gov within 1 year of the primary completion date.

2 months ago

Enrollment change • Trial completion date • Trial termination • Trial primary completion date

EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1) • BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • NTRK (Neurotrophic receptor tyrosine kinase)

PD-L1 expression • EGFR mutation • BRAF mutation • ALK translocation

Keytruda (pembrolizumab) • Opdivo (nivolumab) • Avastin (bevacizumab) • cisplatin • Tecentriq (atezolizumab) • Yervoy (ipilimumab) • carboplatin • albumin-bound paclitaxel • pemetrexed • Anktiva (nogapendekin alfa inbakicept-pmln)

2ms

PIPSeN: Trial Evaluating Maintenance Olaparib in Patients With Platinum-sensitive Advanced Non-small Cell Lung Cancer (clinicaltrials.gov)

P2, N=180, Terminated, Gustave Roussy, Cancer Campus, Grand Paris | N=600 --> 180 | Unknown status --> Terminated; study design, change of standard of care, enrollment difficulties

2 months ago

Enrollment change • Trial termination • Platinum sensitive

EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase)

ALK translocation

Lynparza (olaparib)

2ms

Automated extraction of temporalized tumor evolution from oncology EMRs using natural language processing. (PubMed, ESMO Real World Data Digit Oncol)

Reviewing automatically collected data was 5.8 times faster compared with manual collection. Our solution demonstrates robust performance for extracting temporally structured tumor outcomes from EMRs and supports the reconstruction of real-world endpoints in oncology.

2 months ago

Journal

EGFR (Epidermal growth factor receptor) • KRAS (KRAS proto-oncogene GTPase) • ALK (Anaplastic lymphoma kinase)

KRAS mutation • EGFR mutation • ALK translocation

2ms

DIONE-01: A Study to Assess a PI3Kδ Inhibitor (IOA-244) in Patients With Metastatic Cancers (clinicaltrials.gov)

P1, N=210, Active, not recruiting, iOnctura | Trial completion date: Mar 2025 --> Mar 2027

2 months ago

Trial completion date • First-in-human

PD-L1 (Programmed death ligand 1) • BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)

BRAF mutation • BRAF V600 • ALK translocation

PD-L1 IHC 22C3 pharmDx • VENTANA PD-L1 (SP263) Assay

cisplatin • Bavencio (avelumab) • Jakafi (ruxolitinib) • pemetrexed • roginolisib (IOA-244)

3ms

NIBIT-ML-1: A randomized, run-in, phase II study of nivolumab combined with ipilimumab and oral decitabine/cedazuridine (ASTX727) or nivolumab combined with ipilimumab in melanoma and NSCLC patients resistant to anti-PD-1/PD-L1 (2024-518891-29-00)

P1/2, N=148, Recruiting, Fondazione NIBIT Onlus | Not yet recruiting --> Recruiting

3 months ago

Enrollment open

EGFR (Epidermal growth factor receptor) • BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)

EGFR mutation • BRAF mutation • ALK translocation

Opdivo (nivolumab) • Yervoy (ipilimumab) • Inqovi (decitabine/cedazuridine)